Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia

Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia

Patients with asplenia are at high risks of severe infections caused by encapsulated bacteria, particularly Streptococcus pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) are recommended for invasive pneumococcal disease pr...

Full description

Bibliographic Details
Main Authors:	Kenichi Takeshita, Noriko Takeuchi, Yoshiko Takahashi, Chie Fukasawa, Haruka Hishiki, Tadashi Hoshino, Naruhiko Ishiwada, Naoki Shimojo
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-10-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	asplenia serotype specific igg level opsonophagocytic activity 13-valent pneumococcal conjugate vaccine 23-valent pneumococcal polysaccharide vaccine
Online Access:	http://dx.doi.org/10.1080/21645515.2021.1943989

Similar Items

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019-03-01)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
by: Yaru Shi, et al.
Published: (2023-08-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
by: Salil Bendre, et al.
Published: (2024-02-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
by: Salil Bendre, et al.
Published: (2024-02-01)

Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis
by: Melina Gade Sikjær, et al.
Published: (2023-01-01)

Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups
by: Yan Liu, et al.
Published: (2021-01-01)

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020-01-01)

Durability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates: 18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial
by: Lykke Larsen, et al.
Published: (2022-07-01)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01)

Empyema due to Streptococcus Pneumoniae Serotype 9V in a Child Immunized with 13-Valent Conjugated Pneumococcal Vaccine
by: Murat Sütçü, et al.
Published: (2017-02-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)

Analysis of the incidence of community-acquired pneumonia and acute otitis media in children during the first four years of life in different age groups vaccinated with pneumococcal 13-valent vaccine Prevenar
by: S. A. Pyrkova, et al.
Published: (2019-10-01)

Emerging pneumococcal serotypes in Iraq: scope for improved vaccine development [version 2; peer review: 2 approved]
by: Ahmed H. Radhi, et al.
Published: (2023-12-01)

A case report of parapneumonic pleural effusion caused by Streptococcus pneumoniae serotype 19A in a child immunized with 13-valent conjugate pneumococcal vaccine
by: Idrissa Diawara, et al.
Published: (2017-04-01)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
by: Ching-Fen Shen, et al.
Published: (2021-09-01)

Pneumococcal Carriage in Infants Post-PCV10 Introduction in Pakistan: Results from Serial Cross-Sectional Surveys
by: Shahira Shahid, et al.
Published: (2022-06-01)

Temporal changes in nasopharyngeal carriage of Streptococcus pneumoniae serotype 1 genotypes in healthy Gambians before and after the 7-valent pneumococcal conjugate vaccine
by: Chinelo Ebruke, et al.
Published: (2015-04-01)

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine
by: Estelle Méroc, et al.
Published: (2023-07-01)

Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain
by: Pilar Ciruela, et al.
Published: (2022-11-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)

Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study
by: Xiang Guo, et al.
Published: (2024-12-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023-06-01)

A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population
by: Bai Yunhua, et al.
Published: (2022-11-01)

Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world
by: Yadong A. Cui, et al.
Published: (2017-06-01)

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
by: John M. McLaughlin, et al.
Published: (2019-04-01)

A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants
by: Yasunori Ishihara, et al.
Published: (2024-04-01)

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial
by: Bhagirath B. Solanki, et al.
Published: (2017-09-01)

Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution
by: Patricia Izurieta, et al.
Published: (2018-06-01)

Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae among children with acute otitis media in Marrakech, Morocco
by: Sara Amari, et al.
Published: (2022-02-01)

Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly
by: Kenji Kawakami, et al.
Published: (2018-08-01)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
by: Charu Sabharwal, et al.
Published: (2022-11-01)

Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective
by: Xiuyan Li, et al.
Published: (2023-03-01)

A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
by: Soon Min Lee, et al.
Published: (2018-12-01)

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial
by: Wenjuan Wang, et al.
Published: (2022-01-01)

Changes in Invasive Pneumococcal Disease in the Paediatric Population in the Second COVID-19 Pandemic Year
by: Conchita Izquierdo, et al.
Published: (2023-09-01)

<i>Streptococcus pneumoniae</i> Infection in Patients with Asplenia: A Spanish Perspective over a 25-Year Period
by: Enrique Gea-Izquierdo, et al.
Published: (2024-01-01)

Changes in Invasive Pneumococcal Disease Caused by <em>Streptococcus pneumoniae</em> Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
by: Julia C. Bennett, et al.
Published: (2021-03-01)

Immunological and Epidemiological Aspects of the Immunogenicity of Streptococcus Pneumoniae Serotype 3 Capsular Polysaccharide in Pneumococcal Vaccines
by: A. E. Zaitsev, et al.
Published: (2020-04-01)

Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial
by: Lu-Lu Pan, et al.
Published: (2022-11-01)